Knockdown of YAP expression level through a CRISPR/Cas9 genome editing system accompanied with suppression of the expression level of IGF-1R leading to the activation of downstream targets CTGF and CYR61, and thereby could remarkably inhibit tumor cell proliferation and cause cell cycle arrest in DLBCL cells. The gene discussed is IGF1R; the disease is diffuse large B-cell lymphoma.